Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: A multicenter, randomized trial (the LEAD study)

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Bardini, Gianluca ^a   Giorda, Carlo B ^b   Pontiroli, Antonio E ^c   Le Grazie, Cristina ^d   Rotella, Carlo M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Diabetes Unit ASL Turin   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Medical Director   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; BIOLOGICAL MARKER; EZETIMIBE, SIMVASTATIN DRUG COMBINATION; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; UNSPECIFIED SIDE EFFECT; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; ITALY; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ITALY; MALE; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77952466162     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-20     Document Type: Article

References (33)

1. Expert panel on detection evaluation and treatment of high blood cholesterol in adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702, Expert panel on detection evaluation and treatment of high blood cholesterol in adults.
2. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl 2):S1-113. 10.1097/01.hjr.0000277983.23934.c9, 17726407.
3. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91(Suppl 5):v1-52. 1876394, 16365341.
4. Assmann G, Carmena R, Cullen P, Fruchart JC, Jossa F, Lewis B, Mancini M, Paoletti R. Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease. Circulation 1999, 100:1930-1938.
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
6. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822. 10.2337/dc08-9018, 18375431.
7. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. 10.1016/S0140-6736(08)60761-8, 18191683.
8. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009, 16:121-137. 10.1097/HJR.0b013e3283294b1d, 19287307.
9. Avogaro A, Guida P, Giorda C, Mannucci E, Medea G, Comaschi M, Velussi M, Armienti G, Zucchetti R. The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutr Metab Cardiovasc Dis 2007, 17:32-40. 10.1016/j.numecd.2005.12.001, 17174224.
10. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, Jukema JW, Santos RD, Verdejo J, Messig M, McPherson R, Seung KB, Tarasenko L. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34. 10.1161/CIRCULATIONAHA.108.838466, 19546386.
11. Gotto AM. Statins, cardiovascular disease, and drug safety. Am J Cardiol 2006, 97:3C-5C.
12. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007, 18:401-408. 10.1097/MOL.0b013e32825a6773, 17620856.
13. van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, Jones PH, Schaefer EJ. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 2009, 50:730-739. 10.1194/jlr.P800042-JLR200, 2656667, 19043140.
14. Pisciotta L, Fasano T, Bellocchio A, Bocchi L, Sallo R, Fresa R, Colangeli I, Cantafora A, Calandra S, Bertolini S. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis 2007, 194:e116-e122. 10.1016/j.atherosclerosis.2006.10.036, 17140581.
15. Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007, 14:99-108.
16. Merck/Schering-Plough Pharmaceuticals Zetia (ezetimibe) [package insert]. 2008, North Wales, PA, Merck/Schering-Plough Pharmaceuticals, Merck/Schering-Plough Pharmaceuticals.
17. Merck/Schering-Plough Pharmaceuticals Vytorin (ezetimibe/simvastatin) [package insert]. 2009, North Wales, PA, Merck/Schering-Plough Pharmaceuticals, USA, Merck/Schering-Plough Pharmaceuticals.
18. Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, Shah S. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005, 7:88-97. 10.1111/j.1463-1326.2004.00420.x, 15642080.
19. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, Tershakovec AM. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006, 81:1579-1588. 10.4065/81.12.1579, 17165637.
20. Constance C, Westphal S, Chung N, Lund M, McCrary SC, Johnson-Levonas AO, Massaad R, Allen C. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007, 9:575-584. 10.1111/j.1463-1326.2007.00725.x, 17451425.
21. Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin 2008, 24:685-694. 10.1185/030079908X273273, 18226326.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Barrios V, Amabile N, Paganelli F, Chen JW, Allen C, Johnson-Levonas AO, Massaad R, Vandormael K. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005, 59:1377-1386. 10.1111/j.1368-5031.2005.00714.x, 16351668.
24. Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004, 148:447-455. 10.1016/j.ahj.2004.03.052, 15389231.
25. Conard S, Bays H, Leiter LA, Bird S, Lin J, Hanson ME, Shah A, Tershakovec AM. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010, 12:210-218. 10.1111/j.1463-1326.2009.01152.x, 20151997.
26. Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004, 20:1437-1445. 10.1185/030079904X2321, 15383192.
27. Brudi P, Vaverkova H, Farnier M, Averna M, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Missault L. Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared with Rosuvastatin 10 mg in High-Risk Patients with and Without Type 2 Diabetes Mellitus (T2DM) [abstract]. J Clin Lipidology 2009, 3:233.
28. Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008, 102:1489-1494. 10.1016/j.amjcard.2008.09.075, 19026302.
29. Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, Vandormael K, Johnson-Levonas AO, Brudi P. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract 2009, 63:547-559. 10.1111/j.1742-1241.2009.02022.x, 19222610.
30. Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008, 102:1495-1501. 10.1016/j.amjcard.2008.09.076, 19026303.
31. Ravid Z, Bendayan M, Delvin E, Sane AT, Elchebly M, Lafond J, Lambert M, Mailhot G, Levy E. Modulation of intestinal cholesterol absorption by high glucose levels: impact on cholesterol transporters, regulatory enzymes, and transcription factors. Am J Physiol Gastrointest Liver Physiol 2008, 295:G873-G885. 10.1152/ajpgi.90376.2008, 18772361.
32. Lally SE, Owens D, Tomkin GH. Sitosterol and cholesterol in chylomicrons of type 2 diabetic and non-diabetic subjects: the relationship with ATP binding cassette proteins G5 and G8 and Niemann-Pick C1-like 1 mRNA. Diabetologia 2007, 50:217-219. 10.1007/s00125-006-0504-0, 17102949.
33. Merck & Co I Zocor (simvastatin) tablets [package insert]. 2008, Whitehouse Station, NJ, Merck & Co. Inc, USA(Package Circular), Merck & Co I.